Want to Live to 125: Find Peter Diamandis Podcast, Blog, & Abundance 360.

What is Human Longevi­ty all about & How is this part­ner­ship going to keep you alive longer?

Recent­ly Human Longevi­ty recent­ly announced a 10 Year Deal with AstraZeneca to sequence and ana­lyze Patient Sam­ples from AstraZeneca Clin­i­cal Tri­als.

The Sig­nif­i­cance of the deal:

Human Longevi­ty, Inc. (HLI), the genomics-based, tech­nol­o­gy-dri­ven com­pa­ny work­ing to rev­o­lu­tion­ize the prac­tice of med­i­cine, has announced a 10 year deal with AstraZeneca to sequence and ana­lyze up to 500,000 DNA sam­ples from AstraZeneca clin­i­cal tri­als. The genom­ic insights from the col­lab­o­ra­tion will be added to the HLI Knowl­edge­base™, build­ing upon what is already the most com­pre­hen­sive data­base of its kind.

What the Big Phar­ma AstraZeneca is doing to make you live longer:

AstraZeneca will share up to 500,000 DNA sam­ples with Human Longevi­ty, Inc., col­lect­ed under option­al informed con­sent in AstraZenenca’s clin­i­cal tri­als over the course of the col­lab­o­ra­tion. HLI will sequence the genomes from these sam­ples and from future sam­ples donat­ed over the next 10 years by patients in AstraZeneca’s tri­als. These data will be shared with AstraZeneca who will also gain access to HLI’s unique data­base, the HLI Knowl­edge­base™, which is slat­ed to have up to 1 mil­lion inte­grat­ed health records with genome, mol­e­c­u­lar and clin­i­cal data by 2020. AstraZeneca will work with HLI’s world-lead­ing machine learn­ing, pat­tern recog­ni­tion and ana­lyt­i­cal tech­niques to inter­pret the genom­ic data.

What AstraZena had to say about this project:

“We are excit­ed to estab­lish this long term rela­tion­ship with AstraZeneca who are now estab­lish­ing them­selves as a leader in genom­ic-focused research,” said J. Craig Ven­ter, Ph.D., Co-founder and CEO, HLI. “We look for­ward to work­ing togeth­er to use HLI’s pro­pri­etary com­pu­ta­tion­al meth­ods and genom­ic data insights to bet­ter inform clin­i­cal tri­als and drug devel­op­ment.”

The HLI Knowl­edge­base™, which was recent­ly award­ed a 2016 Bio-IT World Best Prac­tice Award, is a key tool in the company’s port­fo­lio to trans­form how med­i­cine is prac­ticed. The Knowl­edge­base con­tains tens of thou­sands of high-qual­i­ty sam­ples with genom­ic and phe­no­typ­ic data and can be used to help cus­tomers stream­line drug devel­op­ment, aid in dis­cov­ery of bio­mark­er and com­pan­ion diag­nos­tics, and res­cue and repur­pose drugs from failed clin­i­cal tri­als.

What you need to know about Human Longevi­ty, Inc.™

Human Longevi­ty, Inc. (HLI) is the genomics-based, tech­nol­o­gy-dri­ven com­pa­ny cre­at­ing the world’s largest and most com­pre­hen­sive data­base of whole genome, phe­no­type and clin­i­cal data. HLI is devel­op­ing and apply­ing large scale com­put­ing and machine learn­ing to make nov­el dis­cov­er­ies to rev­o­lu­tion­ize the prac­tice of med­i­cine. HLI’s busi­ness also includes the HLI Health Nucle­us, a genom­ic pow­ered clin­i­cal research cen­ter which uses whole genome sequence analy­sis, advanced clin­i­cal imag­ing and inno­v­a­tive machine learn­ing, along with curat­ed per­son­al health infor­ma­tion, to deliv­er the most com­plete pic­ture of indi­vid­ual health. For more infor­ma­tion, please vis­it http://www.humanlongevity.com or http://www.healthnucleus.com.

Media con­tact: Heather Kowal­s­ki hkowalski@humanlongevity.com 858–361-0466



    Leave a Reply

    Your email address will not be published. Required field are marked *.